{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:12:05Z","timestamp":1794510725732,"version":"4.9.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>FLT3 internal tandem duplications (FLT3-ITD) are major genetic events in acute myeloid leukemia (AML). Although the clinical impact of FLT3-ITD \u201cmacroclones\u201d (allelic ratio [AR] \u22650.05) is well established, the significance of low-level FLT3-ITD subclones (\u201cmicroclones\u201d) remains uncertain. We conducted a post hoc analysis of 1733 patients with newly diagnosed AML enrolled in the Backbone Intergroup 1 trial (ClinicalTrials.gov identifier: NCT02416388). Using next-generation sequencing (NGS), we detected FLT3-ITD microclones (AR between 0.0004 and 0.05) in 17.4% of patients without FLT3-ITD macroclones. Microclones and macroclones (low and high AR) were independently associated with increased relapse risk (cause-specific hazard ratio, 1.50 [95% confidence interval (CI), 1.18-1.91]; 1.98 [1.50-2.62]; and 2.33 [1.69-3.22], respectively) after adjustment for age, white blood cell count, other gene mutations, midostaurin treatment, and allogeneic hematopoietic stem cell transplantation. At 2 years, the cumulative incidence of relapse reached 42.5% (95% CI, 37.0-47.9) in patients with macroclones, 45.1% (38.3-51.6) in patients with microclones, and 29.4% (26.6-32.3) in patients without FLT3-ITD. In NPM1-mutated AML, both microclones and macroclones were associated with higher levels of measurable residual disease (MRD) and increased relapse risk, without independent impact on overall survival after adjustment for MRD. An analysis of paired samples further revealed that 41.8% of relapses in patients with FLT3-ITD microclones at diagnosis were associated with a macroclone at relapse. These findings challenge current risk stratification models and support the integration of NGS-based FLT3-ITD detection into the diagnostic and prognostic workflow for AML. Prospective trials addressing the management of patients with FLT3-ITD microclones are warranted, as is their consideration in future European LeukemiaNet guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032829","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:00:56Z","timestamp":1779382856000},"page":"598-609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic impact of\n                    <i>FLT3<\/i>\n                    -ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"first","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-0873","authenticated-orcid":false,"given":"Romane","family":"Joudinaud","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-1085","authenticated-orcid":false,"given":"Augustin","family":"Boudry","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Centre Hospitalier Universitaire d\u2019Angers, INSERM, Centre National de la Recherche Scientifique, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, F\u00e9d\u00e9ration Hospitalo-Universitaire Grand Ouest Against Leukemia, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-4843","authenticated-orcid":false,"given":"Laur\u00e8ne","family":"Fenwarth","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8721","authenticated-orcid":false,"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-6484","authenticated-orcid":false,"given":"C\u00e9cile","family":"Pautas","sequence":"additional","affiliation":[{"name":"4Department of Hematology, H\u00f4pital Henri Mondor, Assistance Publique-H\u00f4pitaux de Paris, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[{"name":"6Department of Hematology, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Hospital","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8657","authenticated-orcid":false,"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0457-2252","authenticated-orcid":false,"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carre","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Pilar","family":"Gallego-Hernanz","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guieze","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-358X","authenticated-orcid":false,"given":"C\u00e9lestine","family":"Simand","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-6198","authenticated-orcid":false,"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lemasle","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Gabellier","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-0310","authenticated-orcid":false,"given":"Juliette","family":"Lambert","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Centre Hospitalier Universitaire de Versailles, Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[{"name":"20Department of Hematology, H\u00f4pital Necker, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Chraibi","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Centre Hospitalier Universitaire de N\u00eemes, N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sanhes","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Centre Hospitalier de Perpignan, Perpignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Celli-Lebras","sequence":"additional","affiliation":[{"name":"23Acute Leukemia French Intergroup Coordination, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7982-641X","authenticated-orcid":false,"given":"Ariane","family":"Mineur","sequence":"additional","affiliation":[{"name":"24Acute Leukemia French Intergroup Coordination, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Gardin","sequence":"additional","affiliation":[{"name":"25H\u00e9matologie Clinique-H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires Paris Seine Saint-Denis, D\u00e9partement M\u00e9dico-Universitaire H\u00e9matologie-Immunologie, 7\/13 Universit\u00e9 de Paris and Sorbonne Paris Nord, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-850X","authenticated-orcid":false,"given":"Norbert","family":"Ifrah","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Centre Hospitalier Universitaire d\u2019Angers, INSERM, Centre National de la Recherche Scientifique, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, F\u00e9d\u00e9ration Hospitalo-Universitaire Grand Ouest Against Leukemia, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-040X","authenticated-orcid":false,"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault De Latour","sequence":"additional","affiliation":[{"name":"6Department of Hematology, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1275-5422","authenticated-orcid":false,"given":"Lucie","family":"Rigolot","sequence":"additional","affiliation":[{"name":"26Laboratory of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Luquet","sequence":"additional","affiliation":[{"name":"26Laboratory of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Penther","sequence":"additional","affiliation":[{"name":"27Laboratory of Genetics, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[{"name":"6Department of Hematology, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-0753","authenticated-orcid":false,"given":"\u00c9ric","family":"Delabesse","sequence":"additional","affiliation":[{"name":"26Laboratory of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Hamel","sequence":"additional","affiliation":[{"name":"28Department of Biostatistics, Centre Hospitalier Universitaire d\u2019Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"De Botton","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[{"name":"30Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"6Department of Hematology, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-9546","authenticated-orcid":false,"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"1Laboratory of Hematology, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, INSERM U1366, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3548","authenticated-orcid":false,"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[{"name":"30Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2026073011323061200_bib1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITDoes matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"2026073011323061200_bib2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2402622","article-title":"Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy","volume":"16","author":"Boissel","year":"2002","journal-title":"Leukemia"},{"issue":"13","key":"2026073011323061200_bib3","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2026073011323061200_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2026073011323061200_bib5","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2026073011323061200_bib6","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2026073011323061200_bib7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.2012.062638","article-title":"Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia","volume":"97","author":"Nazha","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2026073011323061200_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2026073011323061200_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2024014672","article-title":"Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia","volume":"9","author":"Joudinaud","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"2026073011323061200_bib10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026073011323061200_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026073011323061200_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.26451","article-title":"Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification","volume":"97","author":"Reville","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2026073011323061200_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10388","key":"2026073011323061200_bib14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"The Lancet"},{"issue":"1","key":"2026073011323061200_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data","volume":"15","author":"Spencer","year":"2013","journal-title":"J Mol Diagn"},{"issue":"10","key":"2026073011323061200_bib16","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2026073011323061200_bib17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12859-022-04983-6","article-title":"Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r","volume":"23","author":"Boudry","year":"2022","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"2026073011323061200_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13000-022-01202-x","article-title":"A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication","volume":"17","author":"Kim","year":"2022","journal-title":"Diagn Pathol"},{"issue":"6","key":"2026073011323061200_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/bjh.18800","article-title":"Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis","volume":"201","author":"Yokoyama","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2026073011323061200_bib20","doi-asserted-by":"crossref","first-page":"100534","DOI":"10.1016\/j.modpat.2024.100534","article-title":"Clonal dynamics and relapse risk revealed by high-sensitivity FLT3-internal tandem duplication detection in acute myeloid leukemia","volume":"37","author":"Oduro","year":"2024","journal-title":"Mod Pathol"},{"issue":"7","key":"2026073011323061200_bib21","doi-asserted-by":"crossref","first-page":"EVIDoa2400326","DOI":"10.1056\/EVIDoa2400326","article-title":"Intermediate-dose cytarabine as postinduction AML therapy","volume":"4","author":"Hunault","year":"2025","journal-title":"NEJM Evid"},{"issue":"4","key":"2026073011323061200_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026073011323061200_bib23","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/bjh.70135","article-title":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia","volume":"207","author":"Boudry","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"2026073011323061200_bib24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"2026073011323061200_bib25","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.2024024248","article-title":"Approaching a therapeutic inflection point for FLT3-mutated AML","volume":"145","author":"Perl","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026073011323061200_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2026073011323061200_bib27","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD\u2013mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026073011323061200_bib28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2024-207703","article-title":"Prognostic impact of subclinical FLT3-ITD microclones in patients with acute myeloid leukemia [abstract]","volume":"144","author":"Olson","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026073011323061200_bib29","doi-asserted-by":"crossref","first-page":"e0247093","DOI":"10.1371\/journal.pone.0247093","article-title":"Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia","volume":"16","author":"Mosquera Orgueira","year":"2021","journal-title":"PLoS ONE"},{"issue":"19","key":"2026073011323061200_bib30","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026073011323061200_bib31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026073011323061200_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO-25-01841","article-title":"Quizartinib for newly diagnosed FLT3-internal tandem duplication\u2013negative AML: the randomized, double-blind, placebo-controlled, phase II QUIWI study","volume":"44","author":"Montesinos","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026073011323061200_bib33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2025-1719","article-title":"Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: a subanalysis from the Pethema QUIWI trial [abstract]","volume":"146","author":"Sargas","year":"2025","journal-title":"Blood"},{"issue":"suppl 16","key":"2026073011323061200_bib34","first-page":"TPS6580","article-title":"QuANTUM-Wild: a phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD\u2013negative acute myeloid leukemia (AML) [abstract]","volume":"43","author":"Montesinos","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026073011323061200_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/598\/2535854\/blood_bld-2025-032829-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/598\/2535854\/blood_bld-2025-032829-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:32:40Z","timestamp":1785425560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/5\/598\/568611\/Prognostic-impact-of-FLT3-ITD-microclones-in-young"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032829","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,30]]},"published":{"date-parts":[[2026,7,30]]}}}